Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Period:
Draw Mode:
| Volume | 1,372 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Xilio Therapeutics Inc | XLO | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.02 | 1.63% | 1.25 | 07:49:37 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 1.23 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 15 | 1,372 | - | 0.49 - 3.40 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 07:44:11 | 1 | $ 1.23 | USD |
Xilio Therapeutics Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 33.88M | 27.54M | - | 0 | -76.4M | -2.77 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Xilio Therapeutics News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical XLO Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 1.30 | 1.40 | 1.18 | 1.26 | 381,141 | -0.05 | -3.85% |
| 1 Month | 0.70 | 1.93 | 0.58 | 1.26 | 3,540,939 | 0.55 | 78.57% |
| 3 Months | 0.622 | 1.93 | 0.5001 | 1.21 | 1,273,912 | 0.628 | 100.96% |
| 6 Months | 1.98 | 2.8938 | 0.49 | 1.16 | 670,204 | -0.73 | -36.87% |
| 1 Year | 3.21 | 3.40 | 0.49 | 1.19 | 342,053 | -1.96 | -61.06% |
| 3 Years | 15.00 | 27.95 | 0.49 | 2.76 | 186,407 | -13.75 | -91.67% |
| 5 Years | 15.00 | 27.95 | 0.49 | 2.76 | 186,407 | -13.75 | -91.67% |
Xilio Therapeutics Description
| Xilio Therapeutics Inc is a biotechnology company focused on harnessing the immune system to achieve deep and durable clinical responses to improve the lives of patients with cancer. Leveraging the GPS platform, they are building a pipeline of tumor-selective cytokine and checkpoint inhibitor immunotherapies to treat cancer. The goal is to overcome the limitations of current I-O therapies by developing products with an improved therapeutic index. |
